EP Patent

EP2990800A1 — Neprilysin as heartfailure (HF) prognostic marker

Assigned to Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP · Expires 2016-03-02 · 10y expired

What this patent protects

The present invention provides an in vitro method for determining the prognosis in a patient suffering a heart failure disease, the method comprising the step of determining the level of soluble neprilysin (NEP) in a test sample of the patient.

USPTO Abstract

The present invention provides an in vitro method for determining the prognosis in a patient suffering a heart failure disease, the method comprising the step of determining the level of soluble neprilysin (NEP) in a test sample of the patient.

Drugs covered by this patent

Patent Metadata

Patent number: EP2990800A1
Jurisdiction: EP
Classification: —
Expires: 2016-03-02
Drug substance claim: No
Drug product claim: No
Assignee: Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.